We see Sumitomo Pharma Co., Ltd. (4506.T) as one of the most active names on the JPX intraday tape. The stock trades at JPY 1,920.50, up 4.09% on volume of 32,261,200 shares. Momentum stems from heavy buying and a rebound from the 200-day average. We track valuation, cash flow, and technicals to connect the news flow to price action for active traders and investors watching 4506.T stock.

Intraday price action and volume for 4506.T stock

4506.T stock opened at JPY 1,811.50 and hit a session high of JPY 2,028.50. The intraday rise of JPY 75.50 equals 4.09%. Volume at 32,261,200 is 2.76 times average volume, marking it among JPX’s most active stocks. High relative volume supports a sustained move, but traders should watch the 50-day average JPY 2,426.22 as a nearby supply zone.

Fundamentals and valuation context for 4506.T stock

Sumitomo Pharma (4506.T) reports EPS JPY 389.48 and a trailing PE of 4.93. Price-to-book sits near 2.64 and debt-to-equity is 0.90. Net margins run at 24.28% and return on equity is 48.92%. These metrics show strong profitability versus healthcare peers, but elevated intangible assets raise PB scrutiny. We connect low PE to earnings strength and sector comparisons when assessing 4506.T stock valuation.

Technical and momentum signals for 4506.T stock

Technicals show mixed momentum for 4506.T stock. RSI is 38.31, indicating a neutral-to-oversold tone. MACD histogram is negative, and ADX at 20.43 implies a weak trend. Bollinger bands span JPY 1,682.53 to JPY 3,128.27, leaving room for volatility. Traders should watch day low JPY 1,792.00 and day high JPY 2,028.50 for breakout confirmation.

News flow and catalysts driving 4506.T stock trading

Recent headlines mention Sumitomo Pharma activity across Asian markets and analyst commentary. Short-term flows appear driven by sector rotation into healthcare and selective buying by institutional desks. See recent market summaries for context source and regional market coverage source. We view news as supportive but not yet catalytic for a multi-session trend in 4506.T stock.

Meyka AI grade and analyst-grade outlook for 4506.T stock

Meyka AI rates 4506.T with a score out of 100: 75.57 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights strong ROE, cash flow, and a low PE as positives. Debt structure and intangible-heavy book value are flagged as risks. We present grade context, not investment advice.

Price targets, forecast and risk factors for 4506.T stock

Meyka AI’s forecast model projects a near-term monthly level of JPY 2,553.62, a quarterly level of JPY 2,132.41, and a one-year model value of JPY 865.16. Against the current JPY 1,920.50, the monthly projection implies an upside of 32.97%. We set pragmatic price targets: base case JPY 2,600.00, bull case JPY 3,300.00, and bear case JPY 1,500.00. Risks include regulatory setbacks, pipeline trial delays, and sector rotation away from healthcare.

Final Thoughts

Key takeaways for 4506.T stock: intraday demand pushed the price to JPY 1,920.50, up 4.09%, on outsized volume of 32,261,200 shares. Fundamentals remain supportive: PE 4.93, EPS JPY 389.48, and ROE 48.92% point to strong earnings capacity. Technicals are mixed, with RSI 38.31 and MACD negative, so confirm strength above JPY 2,028.50 before assuming continuation. Meyka AI’s short-term forecast implies a 32.97% upside to JPY 2,553.62, while company-specific risks could limit gains. For active traders, watch volume, the 50-day average JPY 2,426.22, and news catalysts. Institutional investors should weigh valuation against intangible assets and debt-to-equity 0.90. Meyka AI provides this AI-powered market analysis platform insight to help frame trading and investment decisions, but these are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.